Mylan Laboratories Limited Ramipril Export Data — India (DGFT 2022–2026)

Name: Mylan Laboratories Limited Ramipril Export Records India — #1 Exporter, 320 Shipments, $16.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Ramipril

India Pharmaceutical Trade Intelligence

$89.8M177 Suppliers93 CountriesHS 30049071

ExportsIndia → UNITED KINGDOM35.0%India → FRANCE23.2%

ImportsMALTA → India$520.7K GERMANY → India$469.4K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: CSP VIATRIS

Mylan Laboratories Limited — Ramipril Exporter #1 | $16.0M Trade Value | TransData Nexus | TransData Nexus

Mylan Laboratories Limited — Ramipril Exporter Profile

Indian Pharmaceutical Exporter · #1 for Ramipril · $16.0M export value · DGFT Verified

Mylan Laboratories Limited is the #1 Indian exporter of Ramipril with $16.0M in export value and 320 verified shipments. Mylan Laboratories Limited holds a 17.8% market share in Ramipril exports across 5 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.

Mylan Laboratories Limited — Ramipril Export Profile: Buyers & Destinations

Mylan Laboratories Limited Ramipril export treemap — buyers and destination countries | TransData Nexus

Where Does Mylan Laboratories Limited Export Ramipril?

Country	Value	Shipments	Share
FRANCE	$6.4M	305	98.4%
NETHERLANDS	$40.0K	1	0.6%
UNITED ARAB EMIRATES	$34.8K	3	0.5%
UNITED STATES	$13.9K	3	0.2%
ITALY

Who Are the Top Buyers of Ramipril from Mylan Laboratories Limited?

Buyer	Country	Value	Orders
CSP VIATRIS SANTE AT CSP-LAB	FRANCE	$919.2K	41
CSP MYLAN SAS AT CSP LABO 274	FRANCE	$904.3K	37
M/S. CSP MYLAN SAS AT CSP LABO 274	FRANCE	$770.3K	33
CSP VIATRIS SANTE AT CSP- LAB,	FRANCE	$547.0K	44
CSP VIATRIS SANT? AT CSP- LAB	FRANCE	$491.3K	20
CSP VIATRIS SANTE AT CSP- LABO,	FRANCE	$450.4K	19
CSP VIATRIS SANTE AT CSP- LAB	FRANCE	$448.0K	23
CSP VIATRIS SANTE AT CSP LAB	FRANCE	$428.6K	18
CSP MYLAN SAS AT CSP- LABO 274,	FRANCE	$408.4K	17
CSP	FRANCE	$294.5K	16

Mylan Laboratories Limited supplies Ramipril to 18 buyers globally. The largest buyer is CSP VIATRIS SANTE AT CSP-LAB (FRANCE), followed by CSP MYLAN SAS AT CSP LABO 274 (FRANCE) and M/S. CSP MYLAN SAS AT CSP LABO 274 (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Ramipril Formulations Does Mylan Laboratories Limited Export?

Product Description / Formulation	Value	Shipments
HARMLESS MEDICINES, RAMIPRIL MYLAN 10MG	$168.6K	6
RAMIPRIL MYLAN 10 MG 90 BS PACKS 19062	$114.5K	3
RAMIPRIL MYLAN 10 MG 90 BS PACKS 18949	$113.8K	3
RAMIPRIL 1.25MG 90BL VIA FR (34470 PACKSX 9 X 10'S = 3102300 NOS)	$104.2K	3
HARMLESS MEDICINES, RAMIPRIL MYLAN 2.5MG	$101.9K	5
HARMLESS MEDICINES, RAMIPRIL MYLAN 5MG 3	$100.8K	4
RAMIPRIL MYLAN 5 MG 90 BL TAB PACKS 1864	$97.7K	4
RAMIPRIL 2.5MG 90BS VIA FR PACKS 79097	$91.0K	3
RAMIPRIL MYLAN 10MG 30BS PACKS 56224	$83.2K	2
RAMIPRIL TAB 5MG 90BL FR VIA (PACKS : 9 X 10'S BLISTER) (28925 PACKSX 9 X 10'S = 2603250 NOS)	$80.0K	2

Mylan Laboratories Limited exports 227 distinct Ramipril formulations including tablets, capsules, syrups, and combination drugs. The top formulation is HARMLESS MEDICINES, RAMIPRIL MYLAN 10MG with 6 shipments worth $168.6K.

How Does Mylan Laboratories Limited Compare to Nearest Ramipril Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	MYLAN LABORATORIES LIMITED ★	$16.0M	320	5	$50.0K
2	GENO PHARMACEUTICALS PRIVATE LIMITED	$14.0M	686	1	$20.5K
3	AUROBINDO PHARMA LTD	$13.3M	811	8	$16.4K

Mylan Laboratories Limited ranks #1 among 177 Indian Ramipril exporters. Average shipment value of $50.0K compared to the market average of $466.2K. The closest competitors by value are GENO PHARMACEUTICALS PRIVATE LIMITED and AUROBINDO PHARMA LTD.

Which Indian Ports Ship Ramipril Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	658	13.2%
JNPT/ NHAVA SHEVA SEA	553	11.1%
SAHAR AIR CARGO ACC (INBOM4)	305	6.1%
SAHAR AIR	291	5.8%
JNPT	271	5.4%
DELHI AIR CARGO ACC (INDEL4)	214	4.3%
DELHI AIR	201	4.0%
VIZAG SEA	194	3.9%

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Ramipril Exports

Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.

In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.

The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Ramipril shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 320 individual customs records matching Mylan Laboratories Limited exporting Ramipril, covering 227 formulations to 5 countries via 18 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 93+ countries, 389+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Ramipril

Ramipril

Mylan Laboratories Limited — Ramipril Exporter Profile

Mylan Laboratories Limited — Ramipril Export Profile: Buyers & Destinations

Where Does Mylan Laboratories Limited Export Ramipril?

Who Are the Top Buyers of Ramipril from Mylan Laboratories Limited?

What Is India's Total Ramipril Export Value and How Much Does Mylan Laboratories Limited Contribute?

What Is the Average Shipment Value for Mylan Laboratories Limited's Ramipril Exports?

How Does Mylan Laboratories Limited Compare to Other Indian Ramipril Exporters?

What Ramipril Formulations Does Mylan Laboratories Limited Export?

How Does Mylan Laboratories Limited Compare to Nearest Ramipril Exporters?

Which Indian Ports Ship Ramipril Exports?

What Other Cardiovascular Products Does Mylan Laboratories Limited Export?

Ramipril — Export Intelligence Video

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Ramipril Exports

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

About Mylan Laboratories Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Ramipril Export Data from Mylan Laboratories Limited

Ramipril Stats

Company Overview

Top Products by Mylan Laboratories Limited

Related Analysis

Need Detailed Export Data?

Data Source